AllerT

**AllerT** is an investigational, subcutaneously administered peptide allergen immunotherapy developed by Anergis for birch pollen-induced allergic rhinoconjunctivitis. The product comprises three synthetic contiguous overlapping peptides, designated T1, T2, and T3, spanning T-cell epitopes from **Bet v 1**, the principal birch-pollen allergen, and is formulated with aluminum hydroxide. It was designed to induce allergen-specific immune tolerance while avoiding conformational IgE-binding epitopes of intact Bet v 1. AllerT was evaluated using an ultra-fast preseasonal five-injection regimen over approximately two months in Phase I/IIa and Phase IIb studies. Although early studies reported clinical and immunologic activity, Anergis discontinued development in 2017 after a Phase 2 study identified peptide sensitization and only a modest reduction in seasonal symptoms versus placebo.

Brand names

AllerT

Other names

AllerT SC